Direct Comparison on Disability Prevention
Avonex (interferon beta-1a weekly IM) and Rebif (interferon beta-1a three times weekly SC) show similar efficacy in preventing disability progression in relapsing-remitting multiple sclerosis (RRMS), based on head-to-head trials. The EVIDENCE study (992 patients, 24 months) found Rebif reduced relapse rates by 29% more than Avonex (0.54 vs. 0.76 relapses/year, p=0.0002) and delayed disability progression (time to confirmed 1-point EDSS increase: 45% risk reduction, p=0.0007).[1][2] However, the difference in disability progression was not sustained long-term, and both drugs have comparable overall impact on slowing EDSS progression (a key disability measure) in meta-analyses.[3]
How Clinical Trials Measure Disability
Disability is assessed via EDSS scores (0-10 scale, higher = worse function). Both drugs reduce confirmed EDSS progression by 20-30% vs. placebo in pivotal trials:
- Avonex (Pivotal trial, 301 patients, 2 years): 34% relative risk reduction in progression (p=0.02).[4]
- Rebif (PRISMS trial, 560 patients, 2 years): 29% reduction (p=0.0007).[5]
No trial shows one clearly superior; differences favor Rebif on relapses but not isolated disability endpoints.
Key Head-to-Head Data: EVIDENCE and Beyond
| Trial | Patients | Duration | Disability Outcome (EDSS progression) | Relapse Difference |
|-------|----------|----------|---------------------------------------|--------------------|
| EVIDENCE[1] | 992 (RRMS) | 24 months | Rebif: 19% progressed vs. Avonex 26% (p=0.018, NNT=14) | Rebif 29% lower |
| REFLEXION (extension)[6] | 618 | 5 years | No significant difference (both ~30% progressed) | Rebif sustained edge |
| Meta-analyses[3][7] | >10,000 | Variable | Equivalent hazard ratios (~0.7-0.8 vs. placebo) | - |
Rebif's more frequent dosing may drive slight relapse benefits, but disability rates converge over time.
Side Effects and Tolerability Impacting Long-Term Use
Rebif causes more injection-site reactions (89% vs. 42% Avonex) and flu-like symptoms, leading to higher dropout (12% vs. 7%).[1] Poor adherence reduces real-world disability prevention; Avonex's weekly dosing improves compliance.[8] Liver enzyme elevations and depression risk are similar.
Patient Factors: Who Might Benefit More from Each
- Choose Rebif if: High relapse activity early; tolerable with frequent shots. Younger patients prioritize relapse control.
- Choose Avonex if: Needle phobia or adherence issues; prefer less frequent dosing.
Switching is common; no data shows one prevents disability better post-switch.[9] Neurologists weigh MRI lesions, baseline EDSS, and lifestyle.
Newer Alternatives and Why They Often Replace Both
High-efficacy drugs outperform both for disability prevention:
- Ocrelizumab (35-40% EDSS reduction vs. 20-30%; OPERA trials).[10]
- Fingolimod/natalizumab (similar edges in head-to-heads).[11]
Interferons like Avonex/Rebif are first-line for mild RRMS but lose ground to orals/infusion therapies with better MRI/EDSS data.
[1]: Panitch et al., Neurology 2002 (EVIDENCE). https://n.neurology.org/content/59/4/636
[2]: Mikol et al., Mult Scler 2005.
[3]: Filippini et al., Cochrane 2013. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001996.pub3/full
[4]: Jacobs et al., Ann Neurol 1996.
[5]: PRISMS Study Group, Neurology 1998.
[6]: Kappos et al., Mult Scler 2009.
[7]: Tramacere et al., Cochrane 2015.
[8]: Devonshire et al., Mult Scler 2011.
[9]: MSBase Registry data, 2020.
[10]: Hauser et al., NEJM 2017.
[11]: Montalban et al., NEJM 2018.